TSO3 (TSX:TOS) released their financial results for the second quarter of 2017.
As quoted in the press release:
“We are pleased with our continued operating performance in the second quarter of 2017 as we supported Getinge to market and sell our STERIZONE® VP4 Sterilizers in hospitals in North America and Europe,” stated R. M. (Ric) Rumble, TSO3‘s President and CEO. “We made significant progress during the quarter toward our duodenoscope regulatory claim strategy, enhancing our products and improving our production and service methods. We are looking forward to the months to come.”